All News

steroids.prednisone.pills_.jpg

Glucocorticoids-free zone in SLE?

Md Yuzaiful Md Yusof, MRCP(UK), PhD

For over 70 years, glucocorticoids, (GC) have been a part of standard therapy in SLE. They are classically used to not only induce remission or treat an acute flare, but also as maintenance therapy. They are a valuable 'friend' if used wisely, and can become a 'foe' if used excessively.

Read Article
pregnant, pregnancy, mother, fertility

Pregnancy Updates That Will Change The Way I Practice

Rachel Tate, DO

ACR Convergence is truly drinking from the proverbial fire hose. It’s a beautiful mash-up of basic science and treatment updates meets guidelines, recommendations, and disease identification.

Read Article
lupus.GN_.jpg

Obintuzumab in Lupus Nephritis

EurekAlert

In a post hoc analysis of the phase 2 NOBILITY trial, researchers found that treatment with obinutuzumab—an antibody that targets a protein expressed on certain immune cells—was superior to placebo for preserving kidney function and preventing flares in patients with lupus nephritis, a kidney con

Read Article
RheumNow Podcast square

Subcutaneous Biosimilars? (10.27.2023)

Jack Cush, MD

Dr. Jack Cush reviews RheumNow's top entries the PMR Campaign, news, journal reports and regulatory actions.

Read Article
Clot.DVT_.VTE_.blood_.jpg

Anti-Phospholipid Antibodies - Infrequent in Certain Groups

MedPage Today

Among patients with systemic lupus erythematosus (SLE), high titers of anti-phospholipid (aPL) antibodies were most prevalent in whites and Latinos and less so for Black and Asian individuals, researchers found.

Read Article
RheumNow Podcast square

Methotrexate in OA (10.20.2023)

Jack Cush, MD

Dr. Jack Cush discusses the news, journal articles and regulatory actions. This week we discuss JAKne, DLE and SLE and more.

Read Article
Does knowing ischemic stroke subtypes among SLE patients matter? This study by Hopia et al 👉54% of ischemic strokes in 56 SLE pts were APS/aPL & cardioembolic origin (accdg to TOAST) & +assoc with STAT4 gene. #ACR23 ABST0579 @RheumNow https://t.co/Ut8QPpQNQp
sheila  ( View Tweet)
SLE pts with +aCL IgG/IgM and LA had higher risk of developing atherosclerotic CVD accdg to this prospective study by Ding et al. . . . 🧐Again, SLE pts have ⬆️CV risk so always risk stratify and intervene early. #ACR23 ABST0552 @RheumNow https://t.co/QhttQZzp8G
sheila  ( View Tweet)
This study by Munoz-Grajales et al show that the analyte S100A8/A9 (highest AUC) was able to differentiate between SLE pts with cognitive impairment and those without. . . . Interesting findings. More data needed to confirm and explain why it is so. #ACR23 ABST0558 @RheumNow https://t.co/LcF6s2qgNr
sheila  ( View Tweet)
Acute pregnancy-related CV event risk found to be highest in pts w/ SLE+ APS, followed by primary APS, and SLE w/ LN. Most importantly, 25-30% of events happen post-partum! Monitor these pts carefully! #ACR23 Plenary 0722 #ACRbest https://t.co/yD5VFJ2SXh @rheumnow https://t.co/PDvzbs19fR
Dr. Rachel Tate  ( View Tweet)
Join us tonight at 6pm PT/ 9pm ET for our daily #ACR23 recap. https://t.co/0RDwTdzhwS
Dr. John Cush RheumNow ( View Tweet)
Managing stress is a key in many autoimmune diseases. Do not forget non pharmacological techniques. @RheumNow #ACR23 https://t.co/pACxOSaN7A
Bella Mehta bella_mehta ( View Tweet)
Pregnancy is complicated for women with rheumatic diseases. There's a pathway to healthy mothers & babies, but it takes: - planning - the right meds - the right disease control. @drbags71 #ACR23 Review Course @RheumNow https://t.co/epdDIVGPye
David Liew drdavidliew ( View Tweet)
@drbags71 @RheumNow Too often we don't leave women of childbearing age with a plan, if they do get pregnant. And we need to help them get ready, for whatever they want, so we can avoid bad outcomes - and all the consequences of that. @drbags71 #ACR23 Review COurse @RheumNow https://t.co/HLg6KjCiJX
David Liew drdavidliew ( View Tweet)
@drbags71 @RheumNow So approach @drbags71: HOP-STEP - proactively ask/communicate - make difficult discussions easier with these truly amazing guides: https://t.co/9AJIrF9bsQ counselling https://t.co/618mrifi3f dr/pt Rx plans ⬆️**bookmark these** - share do not miss! #ACR23 Review Course @RheumNow https://t.co/vWwJLu2HWG
David Liew drdavidliew ( View Tweet)
BMJ State of the Art (full read) review of ADVANCES in LUPUS THERAPY (Morand EF, et al). - Recent SLE RCTs - Pathogenesis, genetics, epigenetics - Phenotypes - Emerging treatments - Guidelines on Rx https://t.co/qZFvQkaFeO https://t.co/r9IriOR8FF

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Live registration is NOW OPEN! Early bird pricing through 11/30/2023. Register today! https://t.co/1SjBiM7Daj https://t.co/w2cFcj85r5

Links:

Dr. John Cush RheumNow ( View Tweet)
Anti-Phospholipid Antibodies - Infrequent in Certain Groups Among patients with SLE, high titers of anti-phospholipid (aPL) antibodies were most prevalent in whites and Latinos and less so for Black and Asian individuals, researchers found. https://t.co/qQygcS3Ktw https://t.co/FVKlvFuuFn

Links:

Dr. John Cush RheumNow ( View Tweet)
2023 EULAR Lupus Management Recommendations EULAR has published updated recommendations for the management of systemic lupus erythematosus (SLE) based on new evidence and expert opinion - formulationg five overarching principles and 13 recommendations. https://t.co/9PKvsEUTM3 https://t.co/gElp6tyEQZ

Links:

Dr. John Cush RheumNow ( View Tweet)
2023 EULAR Lupus Management Recommendations EULAR has published updated recommendations for the management of systemic lupus erythematosus (SLE) based on new evidence and expert opinion - formulationg five overarching principles and 13 recommendations. https://t.co/Fzh8F33u3U https://t.co/2baAVsm8Bo

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×